A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer

被引：16
|
作者：
Liu, Hongmei [1 ,2 ]
Ma, Ding [3 ]
Chen, Jinpeng [4 ]
Ye, Li [2 ]
Li, Yiping [5 ]
Xie, Yuexia [2 ]
Zhao, Xue [2 ]
Zou, Hanbing [2 ]
Chen, Xiaojing [2 ]
Pu, Jun [1 ]
Liu, Peifeng [1 ,2 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Cent Lab, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, Dept Biliary Pancreat Surg, Sch Med, Renji Hosp, Shanghai 200127, Peoples R China
[4] Nantong First Peoples Hosp, Thyroid Breast Surg, Nantong 226001, Peoples R China
[5] Shanghai Univ Tradit Chinese Med, Shanghai 200032, Peoples R China
来源：
NANO RESEARCH | 2022年 / 15卷 / 07期
基金：
上海市自然科学基金; 中国国家自然科学基金;
关键词：
multi-drug resistance (MDR); breast cancer; adenosine triphosphate (ATP) responsiveness; epsilon-polylysine; POLY-L-LYSINE; DENDRIMERS; CELL; NANOPARTICLES; GLYCOPROTEIN; CHEMOTHERAPY; EFFICACY; FAMILY;
D O I：
10.1007/s12274-022-4254-1
中图分类号：
O64 [物理化学（理论化学）、化学物理学];
学科分类号：
070304 ; 081704 ;
摘要：
Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified epsilon-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In the in vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible epsilon-polylysine polymers.
引用
收藏
页码：6306 / 6314
页数：9
相关论文
共 50 条
  • [41] Targeting co-delivery of doxorubicin and gefitinib by biotinylated Au NCs for overcoming multidrug resistance in imaging-guided anticancer therapy
    Yang, Jingjing
    Li, Xiaofeng
    Tong, Yao
    Yang, Yufei
    Zhao, Li
    Zhou, Qian
    Xu, Jiawen
    Dong, Lun
    Jiang, Yanyan
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2022, 217
  • [42] Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy
    Zhou, Zilan
    Jafari, Mina
    Sriram, Vishnu
    Kim, Jinsoo
    Lee, Joo-Youp
    Ruiz-Torres, Sasha J.
    Waltz, Susan E.
    MOLECULAR PHARMACEUTICS, 2017, 14 (12) : 4551 - 4559
  • [43] A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer
    Zou, Yifang
    Xiao, Fang
    Song, Liu
    Sun, Bingxue
    Sun, Dandan
    Chu, Di
    Wang, Limei
    Han, Shulan
    Yu, Zhuo
    O'Driscoll, Caitriona M.
    Guo, Jianfeng
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 606
  • [44] Co-Delivery of siRNA and Docetaxel to Cancer Cells by NLC for Therapy
    Senel, Behiye
    Basaran, Ebru
    Akyil, Evrim
    Guven, Umay Merve
    Buyukkoroglu, Gulay
    ACS OMEGA, 2024, 9 (10): : 11671 - 11685
  • [45] Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy
    Zhang, Chuanmin
    Zhang, Shubiao
    Zhi, Defu
    Zhao, Yinan
    Cui, Shaohui
    Cui, Jingnan
    COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2020, 585 (585)
  • [46] Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy
    Guo, Xue-Ling
    Kang, Xiao-Xuan
    Wang, Yue-Qi
    Zhang, Xiao-Jie
    Li, Chang-Jian
    Liu, Yang
    Du, Li-Bo
    ACTA BIOMATERIALIA, 2019, 84 : 367 - 377
  • [47] Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells
    Haggag, Yusuf
    Abu Ras, Bayan
    El-Tanani, Yahia
    Tambuwala, Murtaza M.
    McCarron, Paul
    Isreb, Mohammed
    El-Tanani, Mohamed
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (11) : 1655 - 1669
  • [48] Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy
    Satsangi, Arpan
    Roy, Sudipa S.
    Satsangi, Rajiv K.
    Tolcher, Anthony W.
    Vadlamudi, Ratna K.
    Goins, Beth
    Ong, Joo L.
    BIOMATERIALS, 2015, 59 : 88 - 101
  • [49] Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
    Ngamcherdtrakul, Worapol
    Bejan, Daniel S.
    Cruz-Munoz, William
    Reda, Moataz
    Zaidan, Husam Y.
    Siriwon, Natnaree
    Marshall, Suphalak
    Wang, Ruijie
    Nelson, Molly A.
    Rehwaldt, Justin P. C.
    Gray, Joe W.
    Hynynen, Kullervo
    Yantasee, Wassana
    SMALL, 2022, 18 (11)
  • [50] Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells
    Alinejad, Vahideh
    Somi, Mohammad Hossein
    Baradaran, Behzad
    Akbarzadeh, Parvin
    Atyabi, Fatemeh
    Kazerooni, Hanif
    Kafil, Hosein Samadi
    Maleki, Leili Aghebati
    Mansouri, Homayoon Siah
    Yousefi, Mehdi
    BIOMEDICINE & PHARMACOTHERAPY, 2016, 83 : 229 - 240
12345